IMV, Inc. is a clinical-stage biopharmaceutical company, which engage in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. Its immune-educating technology includes DPX which is designed to inform a specific, coordinated, and persistent anti-tumor immune response. The company was founded on May 18, 2007 and is headquartered in Dartmouth, Canada.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
N/A
Frequently Asked Questions
What is the 52-week high for IMV Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. IMV Inc 52 week high is $0.0195 as of February 25, 2026.